India's Piramal Enterprises made official its intention to purchase Kentucky's Coldstream Laboratories, for $30.6 million, a move that will push the company further into the contract manufacturing of drug delivery components like sterile injectable products, lyophilized (freeze-dried) parenterals, and antibody drug conjugates.
Over the past 6 months the up-and-coming Zymeworks has leveraged its expertise in bispecific antibodies into expanded development pacts with two marquee Big Pharma partners. Later today, positioning itself for what it sees as a pivotal year, the biotech plans to announce another research deal with the prolific Big Biotech Celgene, which is inking one of its classic collaborations sweetened by an upfront payment, an equity stake and up to $164 million per project for a slate of programs that represent its biggest potential payoff yet.
In-transition drug developer AMRI has won a 10-year contract with the National Institutes of Health to help develop and manufacture neurological drugs.
The R&D innovators at Evotec have signed a deal to lend their drug discovery muscle to U.K. biotech C4X Discovery, hoping to develop selective drugs that can combat addiction without druggy side effects.
Catalent has signed a collaboration deal with pharma giant Sanofi, lending out its proprietary approach to crafting antibody-guided treatments.
India's medical device industry will officially open Jan. 21 to unlimited foreign direct investment as the government kicks off what is expected to be a year of vast changes in the way it regulates the products.
Philips announced that it will share anonymized data on more than 100,000 patients collected via its Hospital to Home eICU telehealth initiative with the Massachusetts Institute of Technology.
Belgian drugmaker UCB has inked a $480 million deal to team up with Neuropore Therapies on some early-stage treatments for Parkinson's disease.
Improved access by researchers to corporate clinical trial data, much like open-source software, is expected to help facilitate a conversation between academia and the business world that could both facilitate translational research and help to validate corporate research. Yale University and Johnson & Johnson have announced the first such deal to enable external investigator access to medical device and diagnostics clinical data from J&J.
Partners Intrexon and Ziopharm are cutting in on the fervor over a new class of immunotherapies for cancer, striking a deal with the University of Texas' MD Anderson Cancer Center.